SCHEMBL774074

SCHEMBL774074

CSc1ncc(NC(=O)c2ccc(Cl)c(-c3ccc(-c4ccccc4)cc3)c2)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 3/20 0.52
KCNQ2 O43526 3/20 0.52
POLB P06746 1/20 0.48
THRB P10828 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KCNE1 P15382 2/20 0.46
KCNQ1 P51787 2/20 0.46
KCNQ5 Q9NR82 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
EGFR P00533 1/20 0.46
NTRK1 P04629 1/20 0.46
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46
AXL P30530 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL776898 0.87 KCNQ3 (0.56) KCNQ3KCNQ2MEN1KMT2AKDM4E
SCHEMBL775158 0.84 ABL1 (0.61) KCNQ3KCNQ2MEN1KMT2AKDM4E
SCHEMBL774990 0.83 KCNQ3 (0.59) KCNQ3KCNQ2MEN1KMT2AKDM4E
SCHEMBL774698 0.83 KCNQ3 (0.77) KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL775160 0.81 MAPT (0.56) MEN1KMT2AKDM4ELMNAMAPT
SCHEMBL774620 0.81 KCNQ3 (0.59) KCNQ3KCNQ2MEN1KMT2AKDM4E
SCHEMBL777653 0.81 MEN1 (0.64) KCNQ3KCNQ2MEN1KMT2AKDM4E
SCHEMBL775201 0.80 KCNQ3 (0.58) KCNQ3KCNQ2MEN1KMT2AKDM4E
SCHEMBL3208598 0.79 POLB (0.70) POLBMEN1KMT2AKDM4ELMNA
SCHEMBL3203522 0.78 NAMPT (0.72) KDM4ELMNAMAPTABL1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071513-A1 Compositions and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2012-03-22 US claimed
US-20110178087-A1 Compositions and Their Use as Anti-Tumor Agents Compass Pharmaceuticals LLC. (US) 2011-07-21 US claimed
EP-1802606-B1 ARYLCARBOXAMIDES AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2011-03-16 EP claimed
US-20090018145-A1 Compositions and their use as anti-tumor agents COMPASS PHARMACEUTICALS LLC (US) 2009-01-15 US claimed
US-20120071513-A1 Compositions and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2012-03-22 US disclosed
US-20110178087-A1 Compositions and Their Use as Anti-Tumor Agents Compass Pharmaceuticals LLC. (US) 2011-07-21 US disclosed
EP-1802606-B1 ARYLCARBOXAMIDES AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2011-03-16 EP disclosed
US-20090018145-A1 Compositions and their use as anti-tumor agents COMPASS PHARMACEUTICALS LLC (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071513-A1 Compositions and Their Use as Anti-Tumor Agents TP53, VHL, RB1 KCNQ3 4350/4885KCNQ2 4479/4885POLB 1867/4885
US-20110178087-A1 Compositions and Their Use as Anti-Tumor Agents TP53, VHL, RB1 KCNQ3 4350/4885KCNQ2 4479/4885POLB 1867/4885
US-20090018145-A1 Compositions and their use as anti-tumor agents TP53, VHL, RB1 KCNQ3 4027/4885KCNQ2 4317/4885POLB 1711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.